Endometrium Cancer Clinical Trial
Official title:
Application of Thrombin Gel Matrix for the Prevention of Lymphocele in Patients With Endometrial Cancer.
Verified date | July 2020 |
Source | Kocaeli University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To compare the incidence of lymphocele in Endometrial cancer patients with thrombin gel matrix used and not used during pelvic lymph node dissection.
Status | Completed |
Enrollment | 72 |
Est. completion date | July 2, 2020 |
Est. primary completion date | July 1, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Endometrial cancer patients who need laparotomic bilateral PLND - Patients suitable for surgery Exclusion Criteria: - Previous pelvic surgery - Previous Chemotherapy or Radiotherapy - Patients who undergo only lymph node sampling - Patients who have not signed Informed Consent |
Country | Name | City | State |
---|---|---|---|
Turkey | Kocaeli University | Kocaeli |
Lead Sponsor | Collaborator |
---|---|
Kocaeli University |
Turkey,
Kim YH, Shin HJ, Ju W, Kim SC. Prevention of lymphocele by using gelatin-thrombin matrix as a tissue sealant after pelvic lymphadenectomy in patients with gynecologic cancers: a prospective randomized controlled study. J Gynecol Oncol. 2017 May;28(3):e37. doi: 10.3802/jgo.2017.28.e37. Epub 2017 Feb 28. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of pelvic lymphocele | Frequency pelvic lymphocele at post-operative 2th month | post-operative 2th month | |
Secondary | Volume of radiographic lymphoceles | Volume of lymphocele detected with radiographic imagining at post-operative 2th month (the two largest dimensions measured in centimetres) | post-operative 2th month | |
Secondary | duration of postoperative drainage catheter | duration of postoperative drainage catheter | up to post-operative 1 week | |
Secondary | Postoperative drain amount (ml: milliliters) | Postoperative drain amount (ml: milliliters) | with 1 weeks after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
Completed |
NCT00377520 -
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05902988 -
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06192017 -
Development of a Molecular Diagnostic Tool for Endometrial Cancer.
|
||
Completed |
NCT03899441 -
Multimedia Aid Gynecologic Counseling and Consent
|
N/A | |
Completed |
NCT02552121 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02001623 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02997553 -
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
|
Phase 3 | |
Suspended |
NCT03095664 -
Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT01466777 -
Endometrial Cancer and Robotic-assisted Versus Traditional Laparoscopy
|
N/A | |
Completed |
NCT01068483 -
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
|
Phase 1 | |
Recruiting |
NCT03896113 -
Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT03570866 -
PET/CT in the Management of Patients With Early Stage Endometrial Cancer
|
||
Completed |
NCT05246462 -
The Effect of Logotherapy on Mental Health in Gynecological Cancer Patients
|
N/A | |
Withdrawn |
NCT04464967 -
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT05651282 -
Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer
|
Phase 4 | |
Completed |
NCT06187558 -
Suspension of the Pelvic and Abdominal Organs During Minimally Invasive Surgery
|
||
Completed |
NCT06312917 -
Effect of Physical Activity Intervention on Overweight and Obese Patients With Endometrial Cancer
|
N/A | |
Active, not recruiting |
NCT03951415 -
Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT04212910 -
Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model
|